SecBot SecBot
144 ·Filed Nov 16, 2026

VRTX

VERTEX PHARMACEUTICALS INC / MA
NEUTRAL
Impact 1/10
Horizonimmediate Processed1d 4h ago SEC0001959173-26-008016
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

The sale amount is negligible and routine for director compensation vesting. No material impact on stock expected. Monitor for any larger insider sales or changes in insider filing patterns.

DirectionNeutral
Confidencehigh
Horizonimmediate
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director Sangeeta Bhatia filed a Form 144 notice of intent to sell 271 shares of Vertex Pharmaceuticals, valued at approximately $148,470. The shares were acquired via restricted stock vesting on May 1, 2025, as compensation. The sale is de minimis relative to the company's $137.6B market cap and the insider's total holdings, and is routine for director compensation.

Key Facts

  • Filer: Sangeeta Bhatia, Director of Vertex Pharmaceuticals
  • Shares to be sold: 271 shares of common stock
  • Approximate dollar value: $148,470.06
  • Shares acquired on May 1, 2025 via restricted stock vesting (compensation)
  • Proposed sale date: November 16, 2026
  • Broker: Fidelity Brokerage Services LLC
  • Market cap of Vertex: $137.6B

Financial Impact

Sale of 271 shares valued at ~$148,470, representing approximately 0.0001% of market cap

dilution

Risk Factors

  • Form 144 is an intent to sell; the sale may not be executed
  • No other insider sales context provided beyond this filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (39 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001959173-26-008016
Document: 0001959173-26-008016-index.html0001959173-26-008016
Document: 0001959173-26-008016.txt0001959173-26-008016

Track record

21 reports on VRTX

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +10.87% at T+60 after the Feb 25, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $537.79 Now $531.45 −1.18% settles Nov 24
  2. Nov 16, 20261d ago 144 Neutral 2/10 Entry $543.10 Now $531.45 −2.15% settles Nov 23
  3. Nov 16, 20261d ago 144 Neutral 1/10 Viewing Entry $544.98 Now $531.45 −2.48% settles Nov 23
  4. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $542.00 Now $531.45 −1.95% settles Nov 23
  5. Nov 12, 20265d ago 144 Neutral 2/10 Entry $542.62 Now $531.45 −2.06% settles Nov 19
  6. Nov 6, 202611d ago 144 Neutral 2/10 Entry $547.09 to $538.60 Now $531.45 −2.86% ▼ −1.55% −4.15% vs SPY
  7. Nov 2, 202614d ago 8-K Bullish 6/10 Entry $530.76 to $547.89 Now $531.45 +0.13% ▲ +3.23% +3.81% vs SPY
  8. Oct 22, 202626d ago 3 Neutral 2/10 Entry $523.93 to $558.88 Now $531.45 +1.44% ▲ +6.67% +7.23% vs SPY
  9. Oct 20, 202628d ago 8-K Neutral 2/10 Entry $524.52 to $521.03 Now $531.45 +1.32% ▼ −0.67% −0.22% vs SPY
  10. Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $500.36 to $517.49 Now $531.45 +6.21% ▲ +3.42% +3.57% vs SPY
Showing 10 of 21

US Market Status

Market Open · Closes in 43m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 16, 2026